What each criterion counts, the scoring details that are easy to read two ways, and how the 2024 CHA₂DS₂-VA update changes the number.
How the Revised Cardiac Risk Index is scored, the five details that move a patient between classes, and why published RCRI risk figures differ.
How HAS-BLED is scored, six details that change the total (alcohol units, labile INR on a DOAC, TIA), and what the guidelines say a high score means.
Why PREVENT™ gives lower 10-year ASCVD risk than the pooled cohort equations, the 2026 risk categories, input details, and how to read 30-year risk.
The FDA approved more than 60 oncology drugs in 2024. Fellowship programs built for a slower era can't keep up by adding lectures.
Most cancer patients start treatment in a community clinic, not an academic tower. That model is under siege—and the consequences are already measurable.
